101 related articles for article (PubMed ID: 22018271)
21. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.
De Jong WK; Verpooten GF; Kramer H; Louwagie J; Groen HJ
Anticancer Res; 2009 Jan; 29(1):363-9. PubMed ID: 19331174
[TBL] [Abstract][Full Text] [Related]
22. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
23. Methylation of AKAP12{alpha} promoter in lung cancer.
Jo UH; Whang YM; Sung JS; Kim YH
Anticancer Res; 2010 Nov; 30(11):4595-600. PubMed ID: 21115911
[TBL] [Abstract][Full Text] [Related]
24. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
25. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
26. Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
Virmani AK; Tsou JA; Siegmund KD; Shen LY; Long TI; Laird PW; Gazdar AF; Laird-Offringa IA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):291-7. PubMed ID: 11895880
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
29. [Profile of methylation of certain tumor growth suppressing genes in non-small cell lung cancer].
Zemliakova VV; Zhevlova AI; Zborovskaia IB; Strel'nikov VV; Laktionov KK; Zaletaev DV; Nemtsova MV
Mol Biol (Mosk); 2003; 37(6):983-8. PubMed ID: 14714493
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
31. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
33. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer.
Xinarianos G; McRonald FE; Risk JM; Bowers NL; Nikolaidis G; Field JK; Liloglou T
Hum Mol Genet; 2006 Jul; 15(13):2038-44. PubMed ID: 16698880
[TBL] [Abstract][Full Text] [Related]
34. Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma.
Wang R; Zhang YW; Chen LB
Lung Cancer; 2010 Aug; 69(2):239-44. PubMed ID: 19913326
[TBL] [Abstract][Full Text] [Related]
35. Lung cancer: from single-gene methylation to methylome profiling.
Heller G; Zielinski CC; Zöchbauer-Müller S
Cancer Metastasis Rev; 2010 Mar; 29(1):95-107. PubMed ID: 20099008
[TBL] [Abstract][Full Text] [Related]
36. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features.
Lee SM; Lee JY; Choi JE; Lee SY; Park JY; Kim DS
Cancer Genet Cytogenet; 2010 Feb; 197(1):39-45. PubMed ID: 20113835
[TBL] [Abstract][Full Text] [Related]
38. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
39. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
